Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 1
2007 2
2008 1
2009 1
2010 4
2011 9
2012 7
2013 9
2014 6
2015 15
2016 15
2017 9
2018 14
2019 8
2020 21
2021 24
2022 27
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: . Clear all
Page 1
Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA, Lee JK, Shanmugam V, Marcus CB, Schrock AB, Williams EA, Ritterhouse LL, Hickman RA, Janovitz T, Patel NR, Kroger BR, Ross JS, Mirza KM, Oxnard GR, Vergilio JA, Elvin JA, Benhamida JK, Decker B, Xu ML. Mata DA, et al. Among authors: oxnard gr. Histopathology. 2024 Jun;84(7):1224-1237. doi: 10.1111/his.15168. Epub 2024 Feb 29. Histopathology. 2024. PMID: 38422618
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM, Lee JK, Pasquina LW, Decker B, Vanden Borre P, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP, Schrock AB, Oxnard GR, Lovly CM, Tukachinsky H, Subbiah V. Kasi PM, et al. Among authors: oxnard gr. Clin Cancer Res. 2024 Feb 16;30(4):836-848. doi: 10.1158/1078-0432.CCR-23-2693. Clin Cancer Res. 2024. PMID: 38060240 Free PMC article.
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J, Kalinava N, Doshi P, Pavlick DC, Albacker LA, Ebot EM, Tukachinsky H, Pratt J, Fusaro G, Oxnard GR, Green G, Fabrizio D, Baden J. He J, et al. Among authors: oxnard gr. J Immunother Cancer. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339. J Immunother Cancer. 2023. PMID: 38035725 Free PMC article. Clinical Trial.
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA, Chen KT, Madison R, Newberg JY, Fleischmann Z, Wang S, Sharaf R, Murugesan K, Fendler BJ, Hughes J, Schrock AB, Hegde PS, Oxnard GR, Fabrizio D, Frampton GM, Antonarakis ES, Sokol ES, Jin DX. Moore JA, et al. Among authors: oxnard gr. JCO Precis Oncol. 2023 Sep;7:e2300093. doi: 10.1200/PO.23.00093. JCO Precis Oncol. 2023. PMID: 37769224
186 results